UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number: 001-37599 LivaNova PLC (Exact name of registrant as specified in its cha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number: 001-37599 LivaNova PLC (Exact name of registrant as specified in its charter) England and Wales ................... 98-126815 ...

LivaNova PLC (NASDAQ:LIVN) Q4 2022 Results Earnings Conference Call February 22, 2023 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President, Corporate Development Damien McDonald - Chief Executive Officer Alex Shvartsburg - Chief Financial Officer Conference Call Participants Rick Wise - Stifel Financial Michael Polark - Wolfe Research Matthew Taylor - Jefferies LLC Adam Maeder - Piper Sandler Mike Matson - Needham & Company, LLC Matt Miksic - Barclays Capital Operator Good day, ladies and g ...

Safe Harbor In this presentation, "LivaNova," "the Company," "we," "us" and "our" refer to LivaNova PLC and its consolidated subsidiaries. This report may contain references to our proprietary intellectual property, including among others: • Trademarks for our advanced circulatory support systems: TandemLife™, TandemHeart™, TandemLung™, ProtekDuo™, LifeSPARC™, ALung™, Hemolung™, Respiratory Dialysis™ and ActivMix™. Agenda Financial Results Financial Results 4Q22 Financial Summary Adjusted SG&A % 4Q21 4Q22 • ...

Liva\Nova | --- | --- | --- | --- | |--------------------------------|-------|-------|-------| | | | | | | Health innovation that matters | | | | Third Quarter 2022 Earnings Presentation November 2, 2022 Safe Harbor 2 Certain statements in this presentation, other than purely historical information, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as a ...

LivaNova PLC (NASDAQ:LIVN) Q3 2022 Results Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President, Corporate Development Damien McDonald - Chief Executive Officer Alex Shvartsburg - Chief Financial Officer Conference Call Participants Rick Wise - Stifel Mike Polark - Wolfe Research Matt Taylor - Jefferies Mike Matson - Needham & Company, LLC Adam Maeder - Piper Sandler Amit Hazan - Goldman Sachs Operator Good day, ladies and gentlemen, and welcome to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number: 001-37599 LivaNova PLC (Exact name of registrant as specified in its ...

LivaNova PLC (NASDAQ:LIVN) Q2 2022 Earnings Conference Call August 3, 2022 8:00 AM ET Company Participants Matthew Dodds - SVP, Corporate Development Damien McDonald - CEO & Director Alex Shvartsburg - CFO Conference Call Participants Michael Polark - Wolfe Research Frederick Wise - Stifel, Nicolaus & Company Michael Matson - Needham & Company Adam Maeder - Piper Sandler & Co. Zachary Weiner - Jefferies Anthony Petrone - Mizuho Americas Operator Good day, ladies and gentlemen, and welcome to the LivaNova PL ...

| --- | --- | --- | --- | |----------------------------|-------|-------|-------| | | | | | | Ethan, VNS Therapy Patient | | | | Second Quarter 2022 Earnings Presentation August 3, 2022 Safe Harbor 2 Certain statements in this presentation, other than purely historical information, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number: 001-37599 LivaNova PLC (Exact name of registrant as specified in its char ...